Novo Holdings

Sparrow Quantum Aps. is a Danish company specializing in quantum technology, particularly in the development of advanced light-matter interfaces. The firm focuses on creating deterministic single-photon sources, which are essential for various quantum technologies. Sparrow Quantum boasts the highest efficiency for on-chip single-photon sources globally, characterized by exceptional photon purity, indistinguishability, and outcoupling capabilities. This cutting-edge technology is rooted in over twenty years of research at the renowned Niels Bohr Institute in Copenhagen, from which the company holds exclusive licenses for key patents. By leveraging self-assembled quantum dots paired with slow-light photonic-crystal waveguides, Sparrow Quantum enhances light-matter interactions, providing critical advancements for its clients in the field of photonic quantum technology.

Augustine Therapeutics N.V., founded in 2019 and based in Gent, Belgium, focuses on developing innovative medicines for patients suffering from Charcot-Marie-Tooth disease and other neuromuscular disorders. The company is engaged in two drug discovery programs aimed at identifying new generations of selective HDAC6 inhibitors, which are designed to address axonopathies, including Charcot-Marie-Tooth disease. These novel compounds are intended to protect against nerve degeneration and facilitate the repair of peripheral myelin and axons. By advancing these therapeutic drugs, Augustine Therapeutics aims to enhance the quality of life for patients affected by these debilitating conditions.

Biocomposites Limited specializes in the development, manufacturing, and distribution of calcium compound devices aimed at regenerating and repairing bone and soft tissue. Founded in 1996 and located in Keele, United Kingdom, the company offers a range of innovative products including STIMULAN, a pharmaceutical-grade calcium sulfate for infection management; geneX, an absorbable synthetic bone graft material that accelerates bone growth; and Allogran-R, a calcium phosphate bone substitute providing an osteoconductive scaffold. Additionally, Biocomposites produces Bilok, a synthetic calcium composite used in ligament reconstruction, and Biosteon, a technology designed to enhance implant and bone integration. Their products are utilized in various medical applications, including musculoskeletal infections, bone and joint trauma, spine surgery, and sports injuries, enabling healthcare providers to deliver effective treatment solutions.

Commit Biologics is a biotechnology research company based in Aarhus, Denmark, founded in 2021. The company focuses on developing a novel immunotherapy platform designed for the treatment of various cancers. This platform utilizes b-specific domain antibodies, which are engineered to effectively target and kill tumor cells. The technology is modular, allowing for customization to engage the body's innate immune response. By activating the complement component of the immune system, Commit Biologics aims to provide innovative treatment options for both cancer and autoimmune diseases.

Fire1, based in Dublin, Ireland, is dedicated to developing innovative therapeutic devices aimed at enhancing the lives of heart failure patients. The company has created a remote monitoring system that allows healthcare providers to access real-time patient data and insights. This technology facilitates the early detection of complications associated with heart failure, enabling proactive interventions that can lead to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to address critical challenges in heart failure management and contribute to better healthcare solutions.

Antag Therapeutics ApS is a biotechnology company based in Copenhagen, Denmark, founded in 2017. The company specializes in developing peptide drugs aimed at treating dietary-related metabolic diseases, including obesity, diabetes, and non-alcoholic fatty liver disease. Antag Therapeutics focuses on creating peptide-based GIP receptor antagonists, which are designed to monitor and manage these metabolic conditions by reducing blood flow and lipid uptake in adipose tissue.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapies for advanced liver diseases, including liver fibrosis, cirrhosis, and liver cancer. Established in 2019, Alentis is recognized for its pioneering work in targeting CLDN1+ cancers through the use of anti-CLDN1 antibody-drug conjugates and other therapeutic modalities. The company's research platform incorporates clinically relevant read-outs and single-cell RNA sequencing of patient liver tissues, which aids in understanding and treating fibrotic diseases. Alentis aims to modify and reverse disease progression, ultimately addressing significant health challenges associated with liver-related conditions.

Stingray Marine Solutions AS, based in Oslo, Norway, specializes in developing innovative technology for the aquaculture industry, specifically targeting the removal of sea lice from salmon. Founded in 2010, the company provides an optical delousing solution that utilizes camera vision and laser technology to identify and eliminate sea lice without physically handling the fish. This approach improves fish health management by enhancing production while reducing stress on the animals. The technology is rooted in the patented concept of entrepreneur Esben Beck, who transitioned from the oil and gas sector to focus on aquaculture advancements. Stingray Marine Solutions operates as a subsidiary of Beck Engineering AS, emphasizing in-house design, production, software development, and testing to deliver efficient louse removal systems for salmon farmers.

Oxford Nanopore Technologies is a biotechnology company specializing in nanopore-based sequencing technology for analyzing DNA, RNA, proteins, and small molecules. Its diverse product line includes the portable MinION device, the benchtop PromethION, the GridION system, and Flongle, which caters to on-demand sequencing needs. The technology enables real-time data streaming and is applicable across various fields such as human genomics, cancer research, microbiology, plant science, and environmental studies. Additionally, Oxford Nanopore's products support rapid and accessible molecular analysis, making them suitable for both laboratory and field use. The company's innovations are backed by a robust patent portfolio and are utilized in over 80 countries, addressing needs in healthcare, agriculture, and education. Founded in 2005 and headquartered in Oxford, United Kingdom, Oxford Nanopore also maintains offices in several other countries, enhancing its global reach in advancing genomic research and applications.

HepaRegeniX GmbH, founded in 2016 and based in Ulm, Germany, focuses on developing innovative drugs for acute and chronic liver diseases. The company's therapeutic approach is centered on a proprietary molecular target known as mitogen-activated protein kinase 4 (MKK4), identified as a crucial regulator of liver regeneration through research by Professor Lars Zender and his team at the University Hospital Tübingen. HepaRegeniX aims to create small-molecule inhibitors of MKK4 that can enhance the regenerative capacity of hepatocytes, even in severely diseased livers. This research has significant implications for treating various liver disorders, including nonalcoholic steatohepatitis.

Single Use Support GmbH, founded in 2015 and headquartered in Kufstein, Austria, specializes in manufacturing heavy-duty single-use plastic containers and packaging products for the transportation of liquids, primarily serving the biopharma industry. The company develops innovative bulk filling systems, including BULK.STREAM and RoSS.FILL, designed to enhance fluid logistics processes and prevent losses due to leakages or bio-contamination. By offering tailored packaging solutions, Single Use Support aims to improve the efficiency and safety of liquid logistics in the pharmaceuticals sector.

Commit Biologics is a biotechnology research company based in Aarhus, Denmark, founded in 2021. The company focuses on developing a novel immunotherapy platform designed for the treatment of various cancers. This platform utilizes b-specific domain antibodies, which are engineered to effectively target and kill tumor cells. The technology is modular, allowing for customization to engage the body's innate immune response. By activating the complement component of the immune system, Commit Biologics aims to provide innovative treatment options for both cancer and autoimmune diseases.

NMD Pharma A/S is a clinical-stage biotechnology company based in Aarhus, Denmark, focused on developing small molecule therapies for orphan motor neuron diseases such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials to alleviate symptoms associated with myasthenia gravis. NMD Pharma employs ClC-1 Cl- ion channel inhibitors and utilizes a translational muscle electrophysiology platform to enhance neuromuscular transmission and muscle function. By addressing significant unmet medical needs, NMD Pharma aims to improve the quality of life and survival for patients suffering from various neuromuscular disorders. The company was founded in 2015 and is committed to delivering innovative therapies that transform the lives of individuals affected by these conditions.

Acesion Pharma ApS is a biotech company based in Copenhagen, Denmark, founded in 2011. The company specializes in the development of medical drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. Acesion Pharma focuses on creating SK channel inhibitors, which target specific ion channels in heart cells that are essential for generating the electrical signals that regulate heart rhythm. By inhibiting these channels, the company aims to provide safe and tolerable chronic treatments that prevent the recurrence of AF and support the maintenance of a normal heart rhythm.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapies for advanced liver diseases, including liver fibrosis, cirrhosis, and liver cancer. Established in 2019, Alentis is recognized for its pioneering work in targeting CLDN1+ cancers through the use of anti-CLDN1 antibody-drug conjugates and other therapeutic modalities. The company's research platform incorporates clinically relevant read-outs and single-cell RNA sequencing of patient liver tissues, which aids in understanding and treating fibrotic diseases. Alentis aims to modify and reverse disease progression, ultimately addressing significant health challenges associated with liver-related conditions.

AMSilk GmbH, founded in 2008 and based in Munich, Germany, specializes in producing spider silk proteins and other biomaterials for various industrial applications. The company offers a range of products, including BioShield-S1, a non-immunogenic spider silk film for protective coatings, and biosteel spider silk fibers. Additionally, AMSilk provides wound care products such as SanaSilk, designed to protect the skin, and spider silk-based solutions for surgical applications. Their product portfolio also includes spider silk protein beads and coatings for medical technology, as well as nonwovens for use in filters, wound dressings, and specialty textiles. AMSilk serves multiple sectors, including pharmaceuticals, cosmetics, and technical textiles, and has established a strategic partnership with Gruschwitz Textilwerke AG. The company employs a patented biotechnological process to create biodegradable polymers from silk proteins, enabling the production of various forms such as powders, hydrogels, and fibers that are environmentally friendly.

Fire1, based in Dublin, Ireland, is dedicated to developing innovative therapeutic devices aimed at enhancing the lives of heart failure patients. The company has created a remote monitoring system that allows healthcare providers to access real-time patient data and insights. This technology facilitates the early detection of complications associated with heart failure, enabling proactive interventions that can lead to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to address critical challenges in heart failure management and contribute to better healthcare solutions.

Chromologics is a Danish biotechnology company that specializes in the development of innovative natural food colorants. Originating as a spin-out from the Technical University of Denmark, the company utilizes a fermentation-derived platform to produce novel, sustainable color pigments. These colorants are designed to be stable across various pH levels and temperatures, making them suitable for a wide range of food applications. By offering a bio-based alternative to traditional colorants like carmine, Chromologics aims to support food producers in creating more natural products while enhancing the color of their offerings.

Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications. Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.

Breye Therapeutics, a Danish-based biopharmaceutical firm in the clinical stages, is working to provide cutting-edge oral treatments for the management of retinal vascular diseases.

Biosyntia ApS, established in 2012 and based in Hørsholm, Denmark, is a biotechnology company specializing in the development of biocatalysts for the fermentation of fine chemicals. It leverages synthetic biology and metabolic engineering to create tailored biocatalysts at an accelerated pace and efficiency, using a proprietary high-throughput screening technology. By enabling the production of complex chemical compounds, such as flavors, fragrances, APIs, and pigments, through fermentation, Biosyntia helps manufacturers reduce production costs and environmental impact compared to traditional chemical synthesis methods. The company operates from the Novo Nordisk Foundation Center for Biosustainability and collaborates with fine chemical manufacturers to promote greener and more sustainable production processes.

Precirix is a biotechnology company based in Brussels, Belgium, focused on developing radio-immunotherapeutic drugs for cancer treatment. The company's innovative approach leverages the camelid immune system, utilizing antigen-binding fragments to deliver therapeutic radioisotopes directly to targeted receptors on cancer cell surfaces. This targeted delivery system aims to provide personalized cancer therapies, enhancing treatment efficacy while minimizing side effects. Precirix is actively engaged in clinical development, particularly for cancers that express HER2, and is exploring compounds for various other cancer indications. Established in 2014, the company is committed to advancing a new generation of targeted cancer therapies.

Biomason is a company focused on developing biological cement-based building materials that offer a sustainable alternative to traditional clay and concrete. By utilizing natural microorganisms and innovative chemical processes, Biomason produces biocement at ambient temperatures, significantly reducing the energy consumption typically associated with conventional manufacturing methods. This technology not only provides builders with carbon-free building materials but also aims to eliminate 25% of the concrete industry's global carbon emissions by 2030. Since its inception in 2012, Biomason has successfully implemented its biocement in various projects across the United States and Europe, with its bioLITH precast tile products currently available for commercial use.

NMD Pharma A/S is a clinical-stage biotechnology company based in Aarhus, Denmark, focused on developing small molecule therapies for orphan motor neuron diseases such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials to alleviate symptoms associated with myasthenia gravis. NMD Pharma employs ClC-1 Cl- ion channel inhibitors and utilizes a translational muscle electrophysiology platform to enhance neuromuscular transmission and muscle function. By addressing significant unmet medical needs, NMD Pharma aims to improve the quality of life and survival for patients suffering from various neuromuscular disorders. The company was founded in 2015 and is committed to delivering innovative therapies that transform the lives of individuals affected by these conditions.

Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications. Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.

Chromologics is a Danish biotechnology company that specializes in the development of innovative natural food colorants. Originating as a spin-out from the Technical University of Denmark, the company utilizes a fermentation-derived platform to produce novel, sustainable color pigments. These colorants are designed to be stable across various pH levels and temperatures, making them suitable for a wide range of food applications. By offering a bio-based alternative to traditional colorants like carmine, Chromologics aims to support food producers in creating more natural products while enhancing the color of their offerings.

AMSilk GmbH, founded in 2008 and based in Munich, Germany, specializes in producing spider silk proteins and other biomaterials for various industrial applications. The company offers a range of products, including BioShield-S1, a non-immunogenic spider silk film for protective coatings, and biosteel spider silk fibers. Additionally, AMSilk provides wound care products such as SanaSilk, designed to protect the skin, and spider silk-based solutions for surgical applications. Their product portfolio also includes spider silk protein beads and coatings for medical technology, as well as nonwovens for use in filters, wound dressings, and specialty textiles. AMSilk serves multiple sectors, including pharmaceuticals, cosmetics, and technical textiles, and has established a strategic partnership with Gruschwitz Textilwerke AG. The company employs a patented biotechnological process to create biodegradable polymers from silk proteins, enabling the production of various forms such as powders, hydrogels, and fibers that are environmentally friendly.

The Renewable Energy Partnership is a partnership between Novo Holdings, Sampension, and European Energy with the intention to buy land for the construction of solar and wind farms in Denmark and Sweden. The three partners will provide DKK 650 million (approx. EUR 87 million) with the possibility of investments of up to DKK 1.5 billion (approx. EUR 200 million) through debt financing. This will significantly increase investments in the green transition in Denmark and Sweden.

Deep Branch Biotechnology Ltd., founded in 2018 and based in Nottingham, UK, specializes in carbon recycling services aimed at creating sustainable ingredients for food and feed. By utilizing clean and renewable carbon and energy sources, the company employs a proprietary gas fermentation platform that leverages sustainable feedstocks to produce bio-based products with a significantly reduced carbon footprint. Deep Branch focuses on customer-driven research and development, enabling it to swiftly deliver innovative solutions to meet the growing demand for sustainable food systems. The company collaborates with local suppliers of strategic raw materials, fostering local economies while ensuring a reliable input supply. With a clear roadmap for scaling its operations, Deep Branch has formed strong partnerships across the value chain and has integrated effectively with carbon dioxide suppliers to optimize the deployment of its technology. By producing ingredients that require no arable land and minimal water, Deep Branch is addressing climate change and biodiversity loss, contributing to a more sustainable future without compromising on nutritional quality.

ZELP Ltd. is a London-based company founded in 2017 that specializes in manufacturing a wearable device aimed at reducing methane emissions from livestock. The device works by oxidizing methane into carbon dioxide and includes features such as geolocation, heat detection, early disease detection, and emission frequency monitoring. By providing farmers with tools to measure the volume of oxidized methane, ZELP seeks to significantly mitigate the environmental impact of livestock farming, contributing to more sustainable agricultural practices.

Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications. Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.

The Protein Brewery B.V., founded in 2019 and based in Breda, the Netherlands, specializes in the development, manufacture, and commercialization of sustainable animal-free proteins. The company focuses on producing Fermotein, a fungi-based protein created through advanced fermentation technologies. This innovative approach enables the company to utilize significantly less land and water compared to traditional animal protein production methods, while still delivering high yields and maintaining taste and nutritional quality. The Protein Brewery aims to provide consumers with protein-integrated foods that contain essential amino acids, vitamins, and minerals necessary for a healthy and balanced diet.

VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in the discovery, development, and commercialization of innovative treatments for severe rare diseases, particularly those with significant unmet medical needs. Its lead product candidate, Apraglutide, is a synthetic GLP-2 analog designed to enhance the intestine’s ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support in patients with short bowel syndrome. VectivBio is dedicated to developing best-in-disease therapies that aim to meaningfully improve the lives of patients and their families, providing more than just incremental advancements over existing standard-of-care options.

Lava Therapeutics B.V. is a biotechnology company based in Utrecht, the Netherlands, founded in 2016. The company specializes in developing proprietary bispecific antibodies aimed at engaging gamma-delta T cells for the treatment of both hematological and solid cancers. Its innovative platform, known as the Gammabody platform, is designed to create next-generation bispecific antibodies that activate the immune system to recognize and eliminate tumor cells. By harnessing the potential of γδ T cells, Lava Therapeutics aims to produce potent, safe, and cost-effective biopharmaceuticals that enhance the body's ability to combat cancer, thereby transforming the landscape of cancer treatment.

Chromologics is a Danish biotechnology company that specializes in the development of innovative natural food colorants. Originating as a spin-out from the Technical University of Denmark, the company utilizes a fermentation-derived platform to produce novel, sustainable color pigments. These colorants are designed to be stable across various pH levels and temperatures, making them suitable for a wide range of food applications. By offering a bio-based alternative to traditional colorants like carmine, Chromologics aims to support food producers in creating more natural products while enhancing the color of their offerings.

F2G Ltd is a biotechnology company based in Manchester, United Kingdom, that specializes in developing innovative therapies for serious fungal diseases. Established in 1998, F2G focuses on its F3 series of antifungal compounds, particularly targeting challenging fungi such as Aspergillus and other filamentous molds that pose significant health risks. The company leverages its proprietary genomics technology, MycoBank, to identify critical gene targets in fungi, facilitating the creation of effective antifungal agents. Since its initial funding in 2002, F2G has expanded its research and development capabilities, enabling it to advance its patented compounds and contribute to addressing life-threatening fungal infections that affect individuals with compromised immune systems.

Verona Pharma is a clinical-stage biopharmaceutical company based in London, established in 2005. The company specializes in developing and commercializing therapies for respiratory diseases that have significant unmet medical needs, including chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. Its lead product candidate, ensifentrine, is an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, functioning as both a bronchodilator and an anti-inflammatory agent. Ensifentrine is being developed in various formulations, including nebulized, dry powder inhaler, and pressurized metered-dose inhaler, with the nebulized form currently in Phase 2b clinical development for the maintenance treatment of COPD. Verona Pharma's commitment is to enhance the health and quality of life for individuals suffering from chronic respiratory conditions through innovative therapeutic solutions.

Reapplix ApS, founded in 2008 and based in Birkerod, Denmark, is a research and development company focused on improving wound healing through the use of blood-derived proteins. The company identifies and isolates these proteins to create a tissue regeneration device that provides biological treatment for chronic wounds, particularly diabetic foot ulcers. By utilizing a platform that delivers evidence-based biological wound therapy made entirely from a patient's own blood, Reapplix enables hospitals to offer autologous active cell therapy. This approach allows patients to leverage their own biological materials for enhanced healing outcomes.

NodThera Limited is a biotechnology company based in Little Chesterford, United Kingdom, with additional facilities in Seattle, Washington, and Lexington, Massachusetts. Established in 2016, the company specializes in researching and developing novel inhibitors of the NLRP3 inflammasome to address various inflammatory and neuroinflammatory diseases. NodThera's drug development portfolio includes a range of potent and selective inhibitors aimed at reducing pro-inflammatory cytokines, which are crucial contributors to chronic inflammation. The company's focus encompasses treatments for conditions such as arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers, ultimately enabling healthcare professionals to manage these chronic diseases more effectively.

Antag Therapeutics ApS is a biotechnology company based in Copenhagen, Denmark, founded in 2017. The company specializes in developing peptide drugs aimed at treating dietary-related metabolic diseases, including obesity, diabetes, and non-alcoholic fatty liver disease. Antag Therapeutics focuses on creating peptide-based GIP receptor antagonists, which are designed to monitor and manage these metabolic conditions by reducing blood flow and lipid uptake in adipose tissue.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.

HepaRegeniX GmbH, founded in 2016 and based in Ulm, Germany, focuses on developing innovative drugs for acute and chronic liver diseases. The company's therapeutic approach is centered on a proprietary molecular target known as mitogen-activated protein kinase 4 (MKK4), identified as a crucial regulator of liver regeneration through research by Professor Lars Zender and his team at the University Hospital Tübingen. HepaRegeniX aims to create small-molecule inhibitors of MKK4 that can enhance the regenerative capacity of hepatocytes, even in severely diseased livers. This research has significant implications for treating various liver disorders, including nonalcoholic steatohepatitis.

NorthSea Therapeutics B.V. is a biotechnology company focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Established in 2017 and based in Naarden, the Netherlands, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutic candidates. One of its leading products, icosabutate, is designed to address inflammatory and liver diseases by offering a novel approach to treatment. The company's pipeline includes candidates that aim to improve conditions such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, providing healthcare providers with effective options for patient care.

VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in the discovery, development, and commercialization of innovative treatments for severe rare diseases, particularly those with significant unmet medical needs. Its lead product candidate, Apraglutide, is a synthetic GLP-2 analog designed to enhance the intestine’s ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support in patients with short bowel syndrome. VectivBio is dedicated to developing best-in-disease therapies that aim to meaningfully improve the lives of patients and their families, providing more than just incremental advancements over existing standard-of-care options.

Clario delivers the endpoint technology solutions for clinical trials. Clario fuses scientific expertise and global scale into the broadest endpoint technology platform to enable pharmaceutical, biotech and medical device partners to transform lives. Through Trial Anywhere™, Clario has mastered the ability to generate rich evidence across all trial models: decentralized, hybrid and site-based clinical trials. With 30 facilities in nine countries across North America, Europe and Asia Pacific, Clario's global team of science, technology and operational experts has been delivering the richest clinical evidence for nearly 50 years.

Reapplix ApS, founded in 2008 and based in Birkerod, Denmark, is a research and development company focused on improving wound healing through the use of blood-derived proteins. The company identifies and isolates these proteins to create a tissue regeneration device that provides biological treatment for chronic wounds, particularly diabetic foot ulcers. By utilizing a platform that delivers evidence-based biological wound therapy made entirely from a patient's own blood, Reapplix enables hospitals to offer autologous active cell therapy. This approach allows patients to leverage their own biological materials for enhanced healing outcomes.

Stipe Therapeutics, founded in 2018 and based in Aarhus C, Denmark, develops peptide therapeutics aimed at eliminating tumors and cancer. The company focuses on harnessing the innate immune system to combat cancer by creating first-in-class drugs that target intracellular protein-protein interactions within the STING Pathway. This pathway is a crucial driver of innate immunity and plays a significant role in regulating tumorigenesis and autoimmune disorders. Stipe Therapeutics has successfully identified and validated compounds that sensitize the STING pathway, enabling modulation of the tumor microenvironment to promote a robust anti-tumoral response.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.

Forendo Pharma Oy is a drug discovery and development company based in Turku, Finland, established in 2013. The company focuses on the tissue-specific regulation of sex hormone effects to address various urological and endocrinological diseases. Its key products include Fispemifene, a selective estrogen receptor modulator designed to treat symptoms of low testosterone in men, and a 17HSD1-inhibitor targeting endometriosis. Forendo Pharma aims to enhance treatment options for both men's and women's health by developing innovative therapies that address unmet medical needs in gynecological conditions, such as endometriosis and polycystic ovarian syndrome.

Oxford BioMedica is a biopharmaceutical company based in Oxford, United Kingdom, specializing in the research, development, and manufacturing of lentiviral vector and cell therapy products for various diseases. The company operates through two main segments: Platform and Product. Its LentiVector platform technology enables the integration of therapeutic genes into non-dividing cells, making it suitable for treating conditions affecting the brain and eyes. Oxford BioMedica's product pipeline includes several candidates in various stages of development, targeting diseases such as hematological tumors, age-related macular degeneration, and central nervous system disorders. Additionally, the company has established partnerships with notable firms like Novartis and Bristol Myers Squibb to advance its therapeutic offerings. Oxford BioMedica also focuses on growing its bioprocessing services, leveraging its technologies to provide revenue-generating solutions for third-party clients, while continuing to innovate in gene and cell therapy. Founded in 1995, the company has positioned itself as a leader in the field of gene therapy, addressing unmet medical needs through its advanced therapeutic candidates.

Oxford BioMedica is a biopharmaceutical company based in Oxford, United Kingdom, specializing in the research, development, and manufacturing of lentiviral vector and cell therapy products for various diseases. The company operates through two main segments: Platform and Product. Its LentiVector platform technology enables the integration of therapeutic genes into non-dividing cells, making it suitable for treating conditions affecting the brain and eyes. Oxford BioMedica's product pipeline includes several candidates in various stages of development, targeting diseases such as hematological tumors, age-related macular degeneration, and central nervous system disorders. Additionally, the company has established partnerships with notable firms like Novartis and Bristol Myers Squibb to advance its therapeutic offerings. Oxford BioMedica also focuses on growing its bioprocessing services, leveraging its technologies to provide revenue-generating solutions for third-party clients, while continuing to innovate in gene and cell therapy. Founded in 1995, the company has positioned itself as a leader in the field of gene therapy, addressing unmet medical needs through its advanced therapeutic candidates.

Precirix is a biotechnology company based in Brussels, Belgium, focused on developing radio-immunotherapeutic drugs for cancer treatment. The company's innovative approach leverages the camelid immune system, utilizing antigen-binding fragments to deliver therapeutic radioisotopes directly to targeted receptors on cancer cell surfaces. This targeted delivery system aims to provide personalized cancer therapies, enhancing treatment efficacy while minimizing side effects. Precirix is actively engaged in clinical development, particularly for cancers that express HER2, and is exploring compounds for various other cancer indications. Established in 2014, the company is committed to advancing a new generation of targeted cancer therapies.

Envirotainer AB specializes in the production, development, and rental of active temperature-controlled containers designed for the air transportation of temperature-sensitive healthcare products. Established in 1986 and headquartered in Upplands Väsby, Sweden, the company operates internationally with facilities in major locations such as Singapore, Dallas, Frankfurt, and Toronto, along with a network station in Hyderabad. Envirotainer serves a diverse clientele, including pharmaceutical and biotech companies, by offering a comprehensive suite of services that encompasses laboratory testing, qualification, validation support, and training through the Qualified Envirotainer Program. With over 30 years of experience, Envirotainer has established itself as a leader in secure cold chain solutions, ensuring that pharmaceutical products are transported in a controlled environment to meet the demands of the global market.

Forendo Pharma Oy is a drug discovery and development company based in Turku, Finland, established in 2013. The company focuses on the tissue-specific regulation of sex hormone effects to address various urological and endocrinological diseases. Its key products include Fispemifene, a selective estrogen receptor modulator designed to treat symptoms of low testosterone in men, and a 17HSD1-inhibitor targeting endometriosis. Forendo Pharma aims to enhance treatment options for both men's and women's health by developing innovative therapies that address unmet medical needs in gynecological conditions, such as endometriosis and polycystic ovarian syndrome.

Therachon is a biotechnology company specializing in the development of treatments for rare genetic diseases that lack available therapies. Primarily based in Basel, Switzerland, with research labs in Nice, France, the company is advancing its lead candidate, TA-46, a novel protein therapy aimed at treating achondroplasia, the most prevalent form of short-limbed dwarfism. In addition to its focus on achondroplasia, Therachon is also committed to developing therapeutics targeting rare gastrointestinal and musculoskeletal disorders, with the goal of enabling medical professionals to effectively manage conditions such as short bowel syndrome.

NBE-Therapeutics GmbH, founded in 2012 and based in Basel, Switzerland, specializes in developing antibody-drug conjugates (ADCs) for cancer treatment. The company is focused on creating innovative therapies that aim to enhance survival rates and improve the quality of life for cancer patients globally. Utilizing a proprietary ADC platform, NBE-Therapeutics develops immune-stimulatory therapies that combine potent anthracycline payloads with targeted delivery to tumor cells. This approach not only aims to directly attack cancer cells but also to elicit a durable immunological response against tumors, positioning the company as a significant player in the biopharmaceutical industry dedicated to cancer care.

Inthera Bioscience AG is a private biopharmaceutical company based in Switzerland, established in 2013. The company specializes in developing targeted small molecule therapies aimed at treating solid tumors. Inthera employs a proprietary technology platform to create inhibitors of intracellular protein-protein interactions, which are designed to block aberrant cell signaling associated with cancer. By focusing on rationally designed oral agents, Inthera aims to enhance treatment outcomes for patients with solid tumors. The company is headquartered in Schlieren, Switzerland, and is committed to advancing innovative therapeutic solutions in oncology.

Biosyntia ApS, established in 2012 and based in Hørsholm, Denmark, is a biotechnology company specializing in the development of biocatalysts for the fermentation of fine chemicals. It leverages synthetic biology and metabolic engineering to create tailored biocatalysts at an accelerated pace and efficiency, using a proprietary high-throughput screening technology. By enabling the production of complex chemical compounds, such as flavors, fragrances, APIs, and pigments, through fermentation, Biosyntia helps manufacturers reduce production costs and environmental impact compared to traditional chemical synthesis methods. The company operates from the Novo Nordisk Foundation Center for Biosustainability and collaborates with fine chemical manufacturers to promote greener and more sustainable production processes.

Inventiva Pharma is a clinical-stage biopharmaceutical company based in France, dedicated to developing oral small molecule therapies for patients with significant unmet medical needs, particularly in fibrosis, lysosomal storage disorders, and oncology. The company specializes in drugs that target nuclear receptors, transcription factors, and epigenetic modulation. Its primary product candidate, lanifibranor, is being developed for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved therapies. Inventiva has established a robust pipeline supported by a proprietary discovery engine, a dedicated research and development facility, and a skilled team with extensive experience in drug development. In addition to advancing lanifibranor, the company is also working on several earlier-stage programs aimed at addressing various medical conditions. All operations are conducted in France.

NMD Pharma A/S is a clinical-stage biotechnology company based in Aarhus, Denmark, focused on developing small molecule therapies for orphan motor neuron diseases such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials to alleviate symptoms associated with myasthenia gravis. NMD Pharma employs ClC-1 Cl- ion channel inhibitors and utilizes a translational muscle electrophysiology platform to enhance neuromuscular transmission and muscle function. By addressing significant unmet medical needs, NMD Pharma aims to improve the quality of life and survival for patients suffering from various neuromuscular disorders. The company was founded in 2015 and is committed to delivering innovative therapies that transform the lives of individuals affected by these conditions.

NorthSea Therapeutics B.V. is a biotechnology company focused on developing and manufacturing innovative therapeutics for metabolic, inflammatory, and fibrotic diseases. Established in 2017 and based in Naarden, the Netherlands, the company utilizes its proprietary Structurally Engineered Fatty Acid (SEFA) technology to create unique oral therapeutic candidates. One of its leading products, icosabutate, is designed to address inflammatory and liver diseases by offering a novel approach to treatment. The company's pipeline includes candidates that aim to improve conditions such as dyslipidemia, insulin resistance, hepatic inflammation, and fibrosis, providing healthcare providers with effective options for patient care.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.

Antag Therapeutics ApS is a biotechnology company based in Copenhagen, Denmark, founded in 2017. The company specializes in developing peptide drugs aimed at treating dietary-related metabolic diseases, including obesity, diabetes, and non-alcoholic fatty liver disease. Antag Therapeutics focuses on creating peptide-based GIP receptor antagonists, which are designed to monitor and manage these metabolic conditions by reducing blood flow and lipid uptake in adipose tissue.

Inthera Bioscience AG is a private biopharmaceutical company based in Switzerland, established in 2013. The company specializes in developing targeted small molecule therapies aimed at treating solid tumors. Inthera employs a proprietary technology platform to create inhibitors of intracellular protein-protein interactions, which are designed to block aberrant cell signaling associated with cancer. By focusing on rationally designed oral agents, Inthera aims to enhance treatment outcomes for patients with solid tumors. The company is headquartered in Schlieren, Switzerland, and is committed to advancing innovative therapeutic solutions in oncology.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.

Macrophage Pharma Limited is an immuno-oncology company based in Berkhamsted, United Kingdom, established in 2014. The company specializes in discovering and developing innovative therapies aimed at enhancing anti-tumor immune responses. Its technology platform focuses on the selective delivery of small molecule drugs to tumor-associated macrophages, which activates the body's natural immune system to combat cancer. By harnessing this targeted approach, Macrophage Pharma aims to improve treatment outcomes for patients facing cancer.

NeRRe Therapeutics Ltd. is a biotechnology company based in Stevenage, United Kingdom, specializing in the development of neurokinin (NK) receptor antagonists for clinical and preclinical use. Founded in 2012, the company focuses on creating innovative therapies to address conditions related to neuronal hypersensitivity. Its lead asset, orvepitant, is an oral NK-1 antagonist aimed at treating intense pruritus caused by targeted anti-cancer therapies. In addition to orvepitant, NeRRe's portfolio includes NT-814, a dual NK-1 and NK-3 antagonist, NT-949, a Phase I-ready NK-1 antagonist, and NT-432, a clinical candidate. The company's work targets common and chronic conditions, offering new treatment options for patients suffering from refractory or unexplained cough and other debilitating symptoms.

HepaRegeniX GmbH, founded in 2016 and based in Ulm, Germany, focuses on developing innovative drugs for acute and chronic liver diseases. The company's therapeutic approach is centered on a proprietary molecular target known as mitogen-activated protein kinase 4 (MKK4), identified as a crucial regulator of liver regeneration through research by Professor Lars Zender and his team at the University Hospital Tübingen. HepaRegeniX aims to create small-molecule inhibitors of MKK4 that can enhance the regenerative capacity of hepatocytes, even in severely diseased livers. This research has significant implications for treating various liver disorders, including nonalcoholic steatohepatitis.

Acesion Pharma ApS is a biotech company based in Copenhagen, Denmark, founded in 2011. The company specializes in the development of medical drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. Acesion Pharma focuses on creating SK channel inhibitors, which target specific ion channels in heart cells that are essential for generating the electrical signals that regulate heart rhythm. By inhibiting these channels, the company aims to provide safe and tolerable chronic treatments that prevent the recurrence of AF and support the maintenance of a normal heart rhythm.

Reapplix ApS, founded in 2008 and based in Birkerod, Denmark, is a research and development company focused on improving wound healing through the use of blood-derived proteins. The company identifies and isolates these proteins to create a tissue regeneration device that provides biological treatment for chronic wounds, particularly diabetic foot ulcers. By utilizing a platform that delivers evidence-based biological wound therapy made entirely from a patient's own blood, Reapplix enables hospitals to offer autologous active cell therapy. This approach allows patients to leverage their own biological materials for enhanced healing outcomes.

NMD Pharma A/S is a clinical-stage biotechnology company based in Aarhus, Denmark, focused on developing small molecule therapies for orphan motor neuron diseases such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials to alleviate symptoms associated with myasthenia gravis. NMD Pharma employs ClC-1 Cl- ion channel inhibitors and utilizes a translational muscle electrophysiology platform to enhance neuromuscular transmission and muscle function. By addressing significant unmet medical needs, NMD Pharma aims to improve the quality of life and survival for patients suffering from various neuromuscular disorders. The company was founded in 2015 and is committed to delivering innovative therapies that transform the lives of individuals affected by these conditions.

Verona Pharma is a clinical-stage biopharmaceutical company based in London, established in 2005. The company specializes in developing and commercializing therapies for respiratory diseases that have significant unmet medical needs, including chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. Its lead product candidate, ensifentrine, is an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, functioning as both a bronchodilator and an anti-inflammatory agent. Ensifentrine is being developed in various formulations, including nebulized, dry powder inhaler, and pressurized metered-dose inhaler, with the nebulized form currently in Phase 2b clinical development for the maintenance treatment of COPD. Verona Pharma's commitment is to enhance the health and quality of life for individuals suffering from chronic respiratory conditions through innovative therapeutic solutions.

F2G Ltd is a biotechnology company based in Manchester, United Kingdom, that specializes in developing innovative therapies for serious fungal diseases. Established in 1998, F2G focuses on its F3 series of antifungal compounds, particularly targeting challenging fungi such as Aspergillus and other filamentous molds that pose significant health risks. The company leverages its proprietary genomics technology, MycoBank, to identify critical gene targets in fungi, facilitating the creation of effective antifungal agents. Since its initial funding in 2002, F2G has expanded its research and development capabilities, enabling it to advance its patented compounds and contribute to addressing life-threatening fungal infections that affect individuals with compromised immune systems.

Clario delivers the endpoint technology solutions for clinical trials. Clario fuses scientific expertise and global scale into the broadest endpoint technology platform to enable pharmaceutical, biotech and medical device partners to transform lives. Through Trial Anywhere™, Clario has mastered the ability to generate rich evidence across all trial models: decentralized, hybrid and site-based clinical trials. With 30 facilities in nine countries across North America, Europe and Asia Pacific, Clario's global team of science, technology and operational experts has been delivering the richest clinical evidence for nearly 50 years.

Acesion Pharma ApS is a biotech company based in Copenhagen, Denmark, founded in 2011. The company specializes in the development of medical drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. Acesion Pharma focuses on creating SK channel inhibitors, which target specific ion channels in heart cells that are essential for generating the electrical signals that regulate heart rhythm. By inhibiting these channels, the company aims to provide safe and tolerable chronic treatments that prevent the recurrence of AF and support the maintenance of a normal heart rhythm.

NMD Pharma A/S is a clinical-stage biotechnology company based in Aarhus, Denmark, focused on developing small molecule therapies for orphan motor neuron diseases such as myasthenia gravis, amyotrophic lateral sclerosis, and spinal muscular atrophy. The company's lead candidate, NMD670, is currently undergoing clinical trials to alleviate symptoms associated with myasthenia gravis. NMD Pharma employs ClC-1 Cl- ion channel inhibitors and utilizes a translational muscle electrophysiology platform to enhance neuromuscular transmission and muscle function. By addressing significant unmet medical needs, NMD Pharma aims to improve the quality of life and survival for patients suffering from various neuromuscular disorders. The company was founded in 2015 and is committed to delivering innovative therapies that transform the lives of individuals affected by these conditions.

Inthera Bioscience AG is a private biopharmaceutical company based in Switzerland, established in 2013. The company specializes in developing targeted small molecule therapies aimed at treating solid tumors. Inthera employs a proprietary technology platform to create inhibitors of intracellular protein-protein interactions, which are designed to block aberrant cell signaling associated with cancer. By focusing on rationally designed oral agents, Inthera aims to enhance treatment outcomes for patients with solid tumors. The company is headquartered in Schlieren, Switzerland, and is committed to advancing innovative therapeutic solutions in oncology.

ObsEva SA is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, dedicated to developing innovative therapeutics for women's reproductive health and pregnancy. Founded in 2012 by Ernest Loumaye and André Chollet, the company focuses on addressing serious conditions such as endometriosis, heavy menstrual bleeding, and preterm labor. Its key products include Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist aimed at treating pain from endometriosis and uterine fibroids, and OBE022, a selective prostaglandin F2α receptor antagonist designed for once-daily treatment of preterm labor. Additionally, ObsEva is advancing Nolasiban, an oral oxytocin receptor antagonist intended to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company operates primarily in Switzerland and is committed to improving outcomes for women facing reproductive health challenges.

Kanyos Bio is focused on developing antigen-specific immune tolerance technology aimed at treating type 1 diabetes and celiac disease. Originating from research at the École Polytechnique Fédérale Lausanne in Switzerland, Kanyos collaborates closely with its sister company, Anokion, and Astellas Pharma to advance its therapeutic offerings. The company is dedicated to creating targeted, disease-modifying therapies that specifically inhibit the immune cells responsible for damage in these conditions, while preserving other immune functions. This precise approach aims to enhance the effectiveness of treatment for patients, potentially leading to better health outcomes.

Biosyntia ApS, established in 2012 and based in Hørsholm, Denmark, is a biotechnology company specializing in the development of biocatalysts for the fermentation of fine chemicals. It leverages synthetic biology and metabolic engineering to create tailored biocatalysts at an accelerated pace and efficiency, using a proprietary high-throughput screening technology. By enabling the production of complex chemical compounds, such as flavors, fragrances, APIs, and pigments, through fermentation, Biosyntia helps manufacturers reduce production costs and environmental impact compared to traditional chemical synthesis methods. The company operates from the Novo Nordisk Foundation Center for Biosustainability and collaborates with fine chemical manufacturers to promote greener and more sustainable production processes.

Acesion Pharma ApS is a biotech company based in Copenhagen, Denmark, founded in 2011. The company specializes in the development of medical drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. Acesion Pharma focuses on creating SK channel inhibitors, which target specific ion channels in heart cells that are essential for generating the electrical signals that regulate heart rhythm. By inhibiting these channels, the company aims to provide safe and tolerable chronic treatments that prevent the recurrence of AF and support the maintenance of a normal heart rhythm.

Glionova AB is a development stage biopharmaceutical company based in Stockholm, Sweden, founded in 2014. The company focuses on developing therapies for challenging cancers, particularly glioblastoma, which is a common and aggressive primary brain tumor. Glionova is advancing its lead product, GLN-1001, an orally bioavailable small molecule designed to induce selective cell death in glioblastoma cells while sparing normal brain tissue. In addition to its research and development efforts, Glionova aims to market its product through strategic partnerships with global pharmaceutical companies that specialize in oncology.

Forendo Pharma Oy is a drug discovery and development company based in Turku, Finland, established in 2013. The company focuses on the tissue-specific regulation of sex hormone effects to address various urological and endocrinological diseases. Its key products include Fispemifene, a selective estrogen receptor modulator designed to treat symptoms of low testosterone in men, and a 17HSD1-inhibitor targeting endometriosis. Forendo Pharma aims to enhance treatment options for both men's and women's health by developing innovative therapies that address unmet medical needs in gynecological conditions, such as endometriosis and polycystic ovarian syndrome.

Adaptimmune Therapeutics, established in 2008, is a UK-based clinical-stage biopharmaceutical company specializing in novel cell therapies for solid tumor patients. Its core technology, the Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform, enables the identification of cancer targets and the development of affinity-enhanced T-cell receptors. Adaptimmune's pipeline includes several SPEAR T-cell therapies in phase I clinical trials, targeting various solid tumors such as urothelial, melanoma, and non-small cell lung cancer. The company has strategic collaborations with GSK, Noile-Immune Biotech, and Universal Cells, Inc. to advance its T-cell therapies.

Pulmologix AB is a Swedish private clinical stage company founded in 2006 and based in Stockholm. The company focuses on developing, manufacturing, and selling an oral non-steroidal anti-asthmatic drug specifically for the treatment of early onset allergic asthma. Pulmologix is dedicated to exploring innovative medical approaches to address respiratory diseases, contributing to advancements in asthma treatment.

Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.

Acacia Pharma Group plc, established in 2007, is a UK-based hospital pharmaceutical company specializing in the discovery, development, and commercialization of products for patients undergoing surgery, invasive procedures, or cancer chemotherapy. Its primary focus is on treating and preventing post-operative nausea and vomiting (PONV) and chemotherapy-induced nausea and vomiting (CINV). Acacia Pharma's lead product, BARHEMSYS, is an intravenous amisulpride for PONV treatment and prophylaxis. Other key products include APD403, an intravenous and oral amisulpride for CINV, and BYFAVO, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic for use in invasive medical procedures. These products primarily serve anesthesiologists and oncologists.

ObsEva SA is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, dedicated to developing innovative therapeutics for women's reproductive health and pregnancy. Founded in 2012 by Ernest Loumaye and André Chollet, the company focuses on addressing serious conditions such as endometriosis, heavy menstrual bleeding, and preterm labor. Its key products include Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist aimed at treating pain from endometriosis and uterine fibroids, and OBE022, a selective prostaglandin F2α receptor antagonist designed for once-daily treatment of preterm labor. Additionally, ObsEva is advancing Nolasiban, an oral oxytocin receptor antagonist intended to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company operates primarily in Switzerland and is committed to improving outcomes for women facing reproductive health challenges.

Avilex Pharma Aps is a biotechnology company based in Copenhagen, Denmark, founded in 2012 as a spin-out from the University of Copenhagen. The company was established by Professor Kristian Strømgaard and Associate Professor Anders Bach, focusing on the development of innovative therapies for various neurological conditions. Avilex Pharma specializes in the creation of dimeric peptides that target PSD95 to address neuropathic pain, as well as the development of inhibitors and neuroprotectants aimed at treating ischemic stroke. By leveraging research from the Department of Drug Design and Pharmacology, the company strives to enhance patient recovery and improve treatment outcomes for those affected by these serious medical conditions.

NeRRe Therapeutics Ltd. is a biotechnology company based in Stevenage, United Kingdom, specializing in the development of neurokinin (NK) receptor antagonists for clinical and preclinical use. Founded in 2012, the company focuses on creating innovative therapies to address conditions related to neuronal hypersensitivity. Its lead asset, orvepitant, is an oral NK-1 antagonist aimed at treating intense pruritus caused by targeted anti-cancer therapies. In addition to orvepitant, NeRRe's portfolio includes NT-814, a dual NK-1 and NK-3 antagonist, NT-949, a Phase I-ready NK-1 antagonist, and NT-432, a clinical candidate. The company's work targets common and chronic conditions, offering new treatment options for patients suffering from refractory or unexplained cough and other debilitating symptoms.

Karus Therapeutics Limited is a biopharmaceutical company based in Oxfordshire, United Kingdom, focused on developing innovative small molecule drugs for cancer treatment. Established in 2005, the company specializes in orally-active drugs that target specific molecular pathways. Its portfolio includes KA2237, a dual-selective inhibitor of PI3K isoforms p110ß and p110d, aimed at treating both hematological and solid tumors, and KA2507, which targets HDAC6 for PD-L1 expressing tumors. Karus Therapeutics combines targeted therapies with immunotherapeutic activity, enabling effective treatment of a variety of cancers as well as immune and inflammatory disorders.

Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company based in Denmark, specializing in the discovery and development of RNA-targeted therapies. Utilizing its proprietary Locked Nucleic Acid (LNA) Drug Platform and Drug Discovery Engine, the company focuses on delivering potent single-stranded LNA-based drug candidates for various disease states. Santaris Pharma's research and development efforts primarily target infectious diseases and cardiometabolic disorders, while also engaging in partnerships with major pharmaceutical companies to address a broader range of therapeutic areas, including cancer, cardiovascular disease, and rare genetic disorders. Founded in 2003, the company holds exclusive worldwide rights for the manufacture and sale of products containing LNA as an active ingredient, supporting its goal of obtaining marketing approval for its innovative therapies.

Alder BioPharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic antibodies to improve treatment for migraine patients in the United States, Australia, and Ireland. The company's lead candidate, eptinezumab, is a monoclonal antibody targeting calcitonin gene-related peptide, currently in late-stage clinical development for migraine prevention. Alder is also developing ALD1910, a preclinical monoclonal antibody aimed at inhibiting pituitary adenylate cyclase-activating polypeptide-38 for similar purposes, and Clazakizumab, which targets the pro-inflammatory cytokine interleukin-6 and has completed two Phase 2b trials. In addition to its product development efforts, Alder engages in strategic collaborations, notably with CSL Limited for advancing clazakizumab as a treatment for solid organ transplant rejection. Incorporated in 2002 and headquartered in Bothell, Washington, Alder operates primarily in the United States, where it generates most of its revenue.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.

Vantia Ltd is a pharmaceutical company based in Southampton, United Kingdom, focused on developing small molecule drugs that address significant unmet medical needs. Established in 2007, the company has a clinical pipeline that includes VA106483, aimed at treating nocturia, a condition that disrupts sleep due to frequent nighttime urination, and VA111913, designed for dysmenorrhea, which involves painful menstrual cramps caused by abnormal uterine contractions. These conditions affect millions of individuals and represent substantial market opportunities. Vantia's strategy involves advancing its proprietary drug candidates through Phase II clinical testing and seeking commercialization through partnerships, positioning itself to make a meaningful impact in the urology and women's health sectors.

Delenex Therapeutics AG is a Swiss biotechnology company focused on developing therapeutic antibody fragments to address serious medical conditions with significant unmet needs. The company specializes in creating antibody fragments intended for local or topical application, leveraging the advantages of antibody therapy while minimizing systemic exposure. Delenex's technology has been clinically validated, enabling the production of antibodies that demonstrate high affinity, solubility, and stability, coupled with a low risk of immunogenicity. This approach aims to enhance therapeutic efficacy while reducing potential side effects associated with traditional systemic antibody treatments.

F-Star Therapeutics is a biopharmaceutical company focused on developing novel bispecific antibody products aimed at improving upon current standards of care, particularly in cancer therapy. The company is uniquely positioned with a strong patent portfolio, enabling it to create and develop Fcab antibody fragments and bispecific antibodies by modifying the constant region of an antibody. F-Star's Modular Antibody Technology allows for rapid discovery and development of bispecific antibodies by adding binding sites to the constant region, facilitating easier production compared to other antibody formats. The company is leveraging this technology to build a pipeline of product candidates. Founded in 2006, F-Star has received significant funding from leading venture capital firms and strategic corporate investors. The company operates out of Cambridge, UK, with over 35 employees dedicated to research and development.

HTG Molecular Diagnostics is a commercial-stage life sciences company based in Tucson, Arizona, that specializes in precision medicine through its innovative molecular profiling technology. The company provides a range of products, including instruments, assay kits, and software, which are integrated into the HTG EdgeSeq platform. This platform automates sample processing and allows for the rapid, reliable profiling of numerous molecular targets from minimal biological samples. HTG's offerings include various molecular profiling panels designed for oncology and immuno-oncology applications, among others. The company serves a diverse clientele, including biopharmaceutical companies, academic research institutions, and molecular testing laboratories, distributing its products directly in the United States and Europe, as well as through international distributors. HTG Molecular Diagnostics has established partnerships with industry leaders to enhance its research and development efforts, further solidifying its role in advancing diagnostic applications and translational medicine. The company was founded in 1997 and was previously known as HTG, Inc. before rebranding in 2011.

Orphazyme is a Copenhagen-based biopharmaceutical company focused on developing innovative therapies for lysosomal storage diseases, a group of serious genetic disorders. The company was founded on research conducted by Professor Marja Jäättela and Thomas Kirkegaard Jensen at the Danish Cancer Society. Orphazyme is engaged in biopharmaceutical research and development, and it has established collaborations with leading academic institutions in Europe and the United States. The company has also entered into a strategic partnership with CombiGene AB, further enhancing its capabilities in the field.

Adenium Biotech ApS is a Danish biopharmaceutical company founded in 2011 and based in Copenhagen. The company specializes in the development and commercialization of antibiotics aimed at treating multi-drug resistant bacterial infections, particularly those acquired in hospital settings. Its primary focus includes complicated urinary tract infections and hospital or ventilator-acquired pneumonia, which are often caused by resistant Gram-negative bacteria such as Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae. Adenium Biotech's lead product, Arenicin, is a non-hemolytic antimicrobial peptide derived from lugworms, demonstrating strong efficacy against Gram-negative pathogens. The company operates as a semi-virtual biotech entity, supported by a team of experts and an international scientific advisory board, with the goal of advancing the Arenicin program through clinical development and regulatory filing.